Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 11Active not recruiting 4Terminated 3Unknown 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Urothelial Cancer 1Melanoma 1Lymphatic Metastasis 1Gestational Trophoblastic Neoplasias (GTN) 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Advanced Solid Tumor 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × avelumab × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡